48
Participants
Start Date
August 31, 2005
Primary Completion Date
March 31, 2008
Study Completion Date
March 31, 2008
Cetuximab + Irinotecan
Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 16 or 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
Cetuximab + Irinotecan
Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
Memorial Sloan Kettering Cancer Center, New York
Sidney Kimmel Cancer Center At Johns Hopkins, Baltimore
Children'S Healthcare Of Atlanta, Atlanta
University Of Florida, Gainesville
Vanderbilt University Medical Center Infectious Diseases, Nashville
University Of Texas Md Anderson Cancer Ctr, Houston
The Children'S Hospital, Denver
Phoenix Children'S Hospital, Phoenix
University Of Arizona Health Sciences Center, Tucson
Eli Lilly and Company
INDUSTRY